ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 148750" data-attributes="member: 13851"><p><strong>ABSTRACT</strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Background:</span></strong> This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Patients and Methods: </span></strong>Eligible TCS were ,55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels #3.0 ng/mL or use of testosterone replacement therapy. We investigated the role of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone–binding globulin (SHBG) locus implicated in increased hypogonadism risk in the general population. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results:</span></strong> Of 491 TCS (median age at assessment, 38.2 years; range, 18.7–68.4 years), 38.5% had hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P5.006) and body mass index of 25 to ,30 kg/m2 (OR, 2.08; P5.011) or $30 kg/m2 (OR, 2.36; P5.005) compared with ,25 kg/m2 . TCS with $2 risk alleles for the SHBG SNPs had a marginally significant increased hypogonadism risk (OR, 1.45; P5.09). Vigorous-intensity physical activity appeared protective (OR, 0.66; P5.07). Type of cisplatin based chemotherapy regimen and socioeconomic factors did not correlate with hypogonadism. Compared with TCS without hypogonadism, those with hypogonadism were more likely to report $2 AHOs (65% vs 51%; P5.003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P,.001) or hypertension (18.5% vs 10.6%; P5.013), and to report erectile dysfunction (19.6% vs 11.9%; P5.018) or peripheral neuropathy (30.7% vs 22.5%; P5.041). A marginally significant trend for increased use of prescription medications for either diabetes (5.8% vs 2.6%; P5.07) or anxiety/ depression (14.8% vs 9.3%; P5.06) was observed. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Conclusions:</span> At a <span style="color: rgb(184, 49, 47)">relatively young median age,</span> more than <span style="color: rgb(184, 49, 47)">one-third of TCS have hypogonadism,</span> which is <span style="color: rgb(44, 130, 201)">significantly associated with increased cardiovascular disease risk factors, and erectile dysfunction.</span> Providers should <span style="color: rgb(184, 49, 47)">screen TCS for hypogonadism and treat symptomatic patients.</span></strong></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusions </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">At a relatively young age,</span> there is <span style="color: rgb(184, 49, 47)">a high prevalence of hypogonadism</span> among <span style="color: rgb(184, 49, 47)">North American TCS treated with modern cisplatin-based chemotherapy.</span></strong> <strong>Major risk factors include<span style="color: rgb(184, 49, 47)"> increasing age and obesity.</span> Hypogonadism was strongly associated with risk factors for CVD.</strong> The clinical value of assessing possible genetic variants in the role of hypogonadism requires further study before these are recommended for use in the clinic. <span style="color: rgb(0, 0, 0)"><strong>In the meantime, </strong></span><span style="color: rgb(184, 49, 47)"><strong>TCS</strong></span><span style="color: rgb(0, 0, 0)"><strong> should be encouraged </strong></span><span style="color: rgb(184, 49, 47)"><strong>to maintain a normal body weight and a healthy lifestyle. </strong></span><strong>Although there are currently <span style="color: rgb(184, 49, 47)">no evidence based guidelines,</span> Bhasin et al recommend that <span style="color: rgb(184, 49, 47)">healthcare providers screen for hypogonadism </span>by surveying TCS for <span style="color: rgb(184, 49, 47)">the classic symptoms of hypogonadism (</span><span style="color: rgb(44, 130, 201)">decreased energy, depressed mood, decreased sexual desire and performance, and night sweats</span><span style="color: rgb(184, 49, 47)">) </span>and <span style="color: rgb(44, 130, 201)">prescribe testosterone replacement therapy</span> to survivors who have <span style="color: rgb(44, 130, 201)">low testosterone levels on 2 occasions and have symptoms related to low testosterone.</span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 148750, member: 13851"] [B]ABSTRACT[/B] [B][COLOR=rgb(184, 49, 47)]Background:[/COLOR][/B] This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. [B][COLOR=rgb(184, 49, 47)]Patients and Methods: [/COLOR][/B]Eligible TCS were ,55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels #3.0 ng/mL or use of testosterone replacement therapy. We investigated the role of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone–binding globulin (SHBG) locus implicated in increased hypogonadism risk in the general population. [B][COLOR=rgb(184, 49, 47)]Results:[/COLOR][/B] Of 491 TCS (median age at assessment, 38.2 years; range, 18.7–68.4 years), 38.5% had hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P5.006) and body mass index of 25 to ,30 kg/m2 (OR, 2.08; P5.011) or $30 kg/m2 (OR, 2.36; P5.005) compared with ,25 kg/m2 . TCS with $2 risk alleles for the SHBG SNPs had a marginally significant increased hypogonadism risk (OR, 1.45; P5.09). Vigorous-intensity physical activity appeared protective (OR, 0.66; P5.07). Type of cisplatin based chemotherapy regimen and socioeconomic factors did not correlate with hypogonadism. Compared with TCS without hypogonadism, those with hypogonadism were more likely to report $2 AHOs (65% vs 51%; P5.003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P,.001) or hypertension (18.5% vs 10.6%; P5.013), and to report erectile dysfunction (19.6% vs 11.9%; P5.018) or peripheral neuropathy (30.7% vs 22.5%; P5.041). A marginally significant trend for increased use of prescription medications for either diabetes (5.8% vs 2.6%; P5.07) or anxiety/ depression (14.8% vs 9.3%; P5.06) was observed. [B][COLOR=rgb(184, 49, 47)]Conclusions:[/COLOR] At a [COLOR=rgb(184, 49, 47)]relatively young median age,[/COLOR] more than [COLOR=rgb(184, 49, 47)]one-third of TCS have hypogonadism,[/COLOR] which is [COLOR=rgb(44, 130, 201)]significantly associated with increased cardiovascular disease risk factors, and erectile dysfunction.[/COLOR] Providers should [COLOR=rgb(184, 49, 47)]screen TCS for hypogonadism and treat symptomatic patients.[/COLOR][/B] [B]Conclusions [/B] [B][COLOR=rgb(184, 49, 47)]At a relatively young age,[/COLOR] there is [COLOR=rgb(184, 49, 47)]a high prevalence of hypogonadism[/COLOR] among [COLOR=rgb(184, 49, 47)]North American TCS treated with modern cisplatin-based chemotherapy.[/COLOR][/B] [B]Major risk factors include[COLOR=rgb(184, 49, 47)] increasing age and obesity.[/COLOR] Hypogonadism was strongly associated with risk factors for CVD.[/B] The clinical value of assessing possible genetic variants in the role of hypogonadism requires further study before these are recommended for use in the clinic. [COLOR=rgb(0, 0, 0)][B]In the meantime, [/B][/COLOR][COLOR=rgb(184, 49, 47)][B]TCS[/B][/COLOR][COLOR=rgb(0, 0, 0)][B] should be encouraged [/B][/COLOR][COLOR=rgb(184, 49, 47)][B]to maintain a normal body weight and a healthy lifestyle. [/B][/COLOR][B]Although there are currently [COLOR=rgb(184, 49, 47)]no evidence based guidelines,[/COLOR] Bhasin et al recommend that [COLOR=rgb(184, 49, 47)]healthcare providers screen for hypogonadism [/COLOR]by surveying TCS for [COLOR=rgb(184, 49, 47)]the classic symptoms of hypogonadism ([/COLOR][COLOR=rgb(44, 130, 201)]decreased energy, depressed mood, decreased sexual desire and performance, and night sweats[/COLOR][COLOR=rgb(184, 49, 47)]) [/COLOR]and [COLOR=rgb(44, 130, 201)]prescribe testosterone replacement therapy[/COLOR] to survivors who have [COLOR=rgb(44, 130, 201)]low testosterone levels on 2 occasions and have symptoms related to low testosterone.[/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top